Clinical Trial Update: A Study of Bevacizumab (Avastin) in Combination With Dacarbazine in Participants With Unresectable/Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab in combination with dacarbazine in unresectable/metastatic melanoma has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Avastin (bevacizumab)
• DTIC-Dome (dacarbazine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Malignant Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2017-04-21